Private Eye

Ad blocking detected

Thank you for visiting CanadianInsider.com. We have detected you cannot see ads being served on our site due to blocking. Unfortunately, due to the high cost of data, we cannot serve the requested page without the accompanied ads.

If you have installed ad-blocking software, please disable it (sometimes a complete uninstall is necessary). Private browsing Firefox users should be able to disable tracking protection while visiting our website. Visit Mozilla support for more information. If you do not believe you have any ad-blocking software on your browser, you may want to try another browser, computer or internet service provider. Alternatively, you may consider the following if you want an ad-free experience.

Canadian Insider Club
$299/ year*
Daily Morning INK newsletter
+3 months archive
Canadian Market INK weekly newsletter
+3 months archive
30 publication downloads per month from the PDF store
Top 20 Gold, Top 30 Energy, Top 40 Stock downloads from the PDF store
All benefits of basic registration
No 3rd party display ads
JOIN THE CLUB

* Price is subject to applicable taxes.

Paid subscriptions and memberships are auto-renewing unless cancelled (easily done via the Account Settings Membership Status page after logging in). Once cancelled, a subscription or membership will terminate at the end of the current term.

Director buying at GeneNews (T:GEN)

Updated Monday May 28, 2018 02:13 AM EDT

Rory Riggs, a Director, acquired 7,022,126 Common Shares on a direct ownership basis at a price of $0.080 through a private transaction on May 22nd, 2018. The insider also acquired 3,511,063 Warrants with an exercise price of $0.120 for 3 years. This represents a $561,770 investment into the company's shares and an account share holdings change of greater than 100%.

GeneNews is in the Biotechnology & Medical Research Sub Industry Group under the Healthcare Sector.

GeneNews Ltd is a Canada-based company focused on developing and commercializing proprietary molecular diagnostic tests for early detection of cancer. It has developed Sentinel Principle platform technology, which determines biomarkers from whole blood. In additional, the Company offers ColonSentry product, it is a blood test to determine an individual's current risk for having colorectal cancer. The Company operates within the biotechnology, molecular diagnostic and genomic biomarker industry. GeneNews has subsidiaries in Canada and the United states. The Company's partners include JTS Health Partners and NueHealth, which are located in the United States.

INK Edge Outlook

CONDITIONS:
Latest
6 months ago
1 year ago
Overall
N/A
N/A
Cloudy
The INK Edge Outlook is a quantitative process that ranks a stock based on our V.I.P. criteria.
View outlooks on all Canadian listed stocks at inkresearch.com.
Two-week free trial for first time users.
Go to Genenews Limited J (GEN)'s company page

Comment On!

140
Upload limit is up to 1mb only
To post messages to your Socail Media account, you must first give authorization from the websites. Select the platform you wish to connect your account to CanadianInsider.com (via Easy Blurb).

Comment On!

No Comments

Twitter

Search (past week) for $GEN.CA

  • No tweets found

Stocktwits